Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 12/20 | 0.46 |
| ▸ | DYRK2 | Q92630 | 7/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 7/20 | 0.43 |
| ▸ | PIM1 | P11309 | 5/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.43 |
| ▸ | CDC42BPB | Q9Y5S2 | 5/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | CLK1 | P49759 | 2/20 | 0.39 |
| ▸ | TTK | P33981 | 1/20 | 0.39 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20508806 | 0.83 | DYRK1A (0.66) | DYRK1ADYRK2DYRK1BPIM1CDK9 | |
| SCHEMBL20163168 | 0.82 | ROCK2 (0.45) | DYRK1ADYRK2DYRK1BPIM1CDK9 | |
| SCHEMBL20162834 | 0.81 | MAPK1 (0.43) | DYRK1ADYRK2DYRK1BPIM1CDK9 | |
| SCHEMBL20162986 | 0.79 | DYRK1A (0.49) | DYRK1ADYRK2DYRK1BPIM1CDK9 | |
| SCHEMBL20162843 | 0.78 | DYRK1A (0.47) | DYRK1ADYRK2DYRK1BPIM1CDK9 | |
| SCHEMBL20162869 | 0.77 | ROCK2 (0.39) | DYRK1AROCK1CDC42BPBROCK2MAPK1 | |
| SCHEMBL20508774 | 0.76 | DYRK1A (0.69) | DYRK1ADYRK2DYRK1BPIM1CDK9 | |
| SCHEMBL19710957 | 0.73 | DYRK1A (0.41) | DYRK1ADYRK2DYRK1BPIM1CDK9 | |
| SCHEMBL12472965 | 0.73 | DYRK1A (0.41) | DYRK1ADYRK2DYRK1BPIM1CDK9 | |
| SCHEMBL20162935 | 0.73 | DYRK1A (0.41) | DYRK1ADYRK2DYRK1BPIM1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250100-A1 | Pyrrolopyrimidines as CFTR Potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC. | 2023-08-10 | — | — | US | disclosed |
| US-20210171534-A1 | Pyrrolopyrimidines as CFTR Potentiators | CYSTIC FIBROSIS FOUNDATION | 2021-06-10 | — | — | US | disclosed |
| US-20200017512-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | PFIZER INC. | 2020-01-16 | — | — | US | disclosed |
| US-20190225621-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION | 2019-07-25 | — | — | US | disclosed |
| US-10301315-B2 | Pyrrolopyrimidines as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20180141954-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171534-A1 | Pyrrolopyrimidines as CFTR Potentiators | CFTR, P2RX1, P2RX5 | DYRK1A 942/4885DYRK2 2061/4885DYRK1B 988/4885 |
| US-20200017512-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CFTR, P2RX1, P2RX5 | DYRK1A 942/4885DYRK2 2061/4885DYRK1B 988/4885 |
| US-20190225621-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CFTR, P2RX1, P2RX5 | DYRK1A 942/4885DYRK2 2061/4885DYRK1B 988/4885 |
| US-20230250100-A1 | Pyrrolopyrimidines as CFTR Potentiators | CFTR, P2RX1, P2RX5 | DYRK1A 942/4885DYRK2 2061/4885DYRK1B 988/4885 |
| US-10301315-B2 | Pyrrolopyrimidines as CFTR potentiators | CFTR, P2RX1, P2RX5 | DYRK1A 902/4885DYRK2 2035/4885DYRK1B 901/4885 |
| US-20180141954-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CFTR, P2RX1, P2RX5 | DYRK1A 902/4885DYRK2 2035/4885DYRK1B 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.